News
-
-
COMMUNIQUÉ DE PRESSE
Rockhaven Resources Ltd. Appoints Axemen Resource Capital As Financial Advisor and Grants an Incentive Stock Option and RSUs
Rockhaven Resources Ltd. appoints Cal Everett and Axemen Resource Capital as Financial Advisors for the Klaza project. Incentive Stock Options and RSUs granted -
-
COMMUNIQUÉ DE PRESSE
NextSource Materials Confirms Uninterrupted Mine Operations and Shipments of SuperFlake(R) Graphite from Madagascar
NextSource Materials confirms operations at the Molo Graphite Mine in Madagascar remain unaffected by the political situation in the country. The company continues its production and shipping of SuperFlake® graphite concentrate with no disruptions -
-
-
COMMUNIQUÉ DE PRESSE
Alset AI Announces Strategic $3 Million Unsecured Term Loan Facility to Advance Flagship Cloud Compute Business Towards Positive Operating Income in 2026
Alset AI secures $3M unsecured term loan from insider for Lyken.AI, aiming to fuel revenue growth and enhance balance sheet with a conservative interest rate of 6%, Alset expecting positive operating income by 2026 -
COMMUNIQUÉ DE PRESSE
Huawei Digital Power Helps ASEAN Achieve Zero-Carbon Transformation with All-Scenario Grid Forming Technologies
Huawei Digital Power showcases grid forming technologies at AEBF-25 in Malaysia, supporting ASEAN's zero-carbon transformation with high-quality Smart PV+ESS solutions and innovations -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire
Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire. Recommandation basée sur l'étude LUNA 3 montrant des améliorations significatives pour les patients -
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
CHMP recommends Sanofi's Wayrilz for EU approval to treat immune thrombocytopenia, targeting disease root cause through multi-immune modulation. Positive phase 3 study results showcased rapid platelet response and symptom improvements
